Article Search

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial Open Access

March 1, 2026

This is an impressive advance in allo transplant, Orca-T cutting moderate–severe cGVHD dramatically (≈13% vs 44%) and nearly doubling cGVHD-free survival at 1 year (78% vs 38%) while also lowering NRM and serious infections is hard to ignore. Overall survival (OS) isn’t statistically different yet, but the combination of better disease control, less toxicity, and preserved immune reconstitution makes this feel like a meaningful step toward safer, more “engineered” transplants rather than just better immunosuppression.

Read More »

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors Available to Purchase

March 1, 2026

This is a nice reminder that immune checkpoint inhibitors (ICI)-associated immune thrombocytopenia (ITP) is uncommon but definitely not benign~1 in 400 incidence with a meaningful subset recurring on rechallenge of 30%, and while most patients recover, severity clearly tracks with worse outcomes including higher mortality. It reinforces that even “rare” hematologic irAEs can carry real clinical weight, so early recognition and thoughtful decisions around rechallenge are key.

Read More »

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial Open Access

March 1, 2026

This is starting to look like a real frontline disruptor in chronic myeloid leukemia (CML), asciminib showing a pretty striking ~22% absolute improvement in MMR at 96 weeks vs investigator-selected TKIs (and nearly 30% over imatinib) with a cleaner tolerability profile makes a strong case for moving beyond ATP-competitive tyrosine kinase inhibitors (TKIs) upfront. The efficacy signal is consistent across depths of response and durability looks excellent, with fewer discontinuations, overall survival (OS) will take time, but this feels very competitive as a new standard option.

Read More »

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years

March 1, 2026

In this Korean retrospective review of >6MM patients, heavy ethanol consumption in patients between 20-39 years of age was associated with associated with about a 20% increased risk of pancreatic cancer. This should be taken with a grain of salt (not on your margarita) but does suggest a dose dependent effect of ethanol use and pancreatic cancer risk.

Read More »

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma

March 1, 2026

This ZSAB‑neoGOLP trial is one of the first randomized neoadjuvant studies in high‑risk resectable intrahepatic cholangiocarcinoma. Neoadjuvant GOLP (gem‑ox + lenvatinib + toripalimab) nearly doubled median event‑free survival, 18.0 vs 8.7 months—and significantly reduced early recurrence, with a strong EFS P<0.001. Two‑year overall survival (OS) numerically favored the neoadjuvant arm (79% vs 61%), though it didn’t cross the stringent interim boundary. Toxicity was manageable (≈28% grade ≥3 during neoadjuvant therapy) and surgery remained feasible, making this a compelling strategy for high‑risk intrahepatic cholangiocarcinoma (ICC) pending longer follow‑up and approval.

Read More »

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

March 1, 2026

CLL17 shows that fixed‑duration venetoclax–obinutuzumab or venetoclax–ibrutinib is noninferior to continuous ibrutinib upfront, with 3‑year PFS ≈80% across all arms. The big difference is depth of response, undetectable MRD was 73% with venetoclax–obinutuzumab, 47% with venetoclax–ibrutinib, and 0% with ibrutinib. Toxicities tracked with mechanism (more cytopenias/infusion reactions with ven‑obinutuzumab, more cardiac events with ibrutinib). Overall, this strongly supports time‑limited therapy as a frontline standard for many chronic lymphocytic leukemia (CLL) patients.

Read More »

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

March 1, 2026

This is the first phase 3 data we’ve had for chemotherapy-induced thrombocytopenia, and romiplostim really moved the needle, 84% of patients were able to avoid CIT-driven dose reductions or delays versus just 36% with placebo, with a risk ratio of 2.8. Platelet nadirs were higher, responses were faster (median ≈1 week), and relative dose intensity was meaningfully better maintained across cycles. Bleeding wasn’t significantly different, but events were numerically lower, and this study wasn’t powered for that. Toxicity was largely chemo-related, with a small signal for thromboembolism (2%), so overall this feels like a practical tool to help maintain dose intensity in gastrointestinal tract (GI) cancers getting oxaliplatin-based regimens.

Read More »

Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

March 1, 2026

This is a strong adjuvant signal in resected stage III dMMR colon cancer, adding atezolizumab to mFOLFOX6 cut the risk of recurrence or death in half and improved 3-year DFS from 76% to 86%. OS hasn’t separated yet, but that may be confounded by immunotherapy at relapse. Toxicity was higher, as expected, with more grade 3–4 events and immune-related adverse events (AE)s, but overall manageable. This feels practice changing for stage III dMMR disease.

Read More »

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

March 1, 2026

Setidegrasib represents a meaningful advance in targeting KRAS G12D–mutant tumors, demonstrating a 36% response rate with median PFS exceeding 8 months in heavily pretreated NSCLC, and a 24% response rate with ~10 month median overall survival (OS) in third line pancreatic cancer, both notable signals in populations lacking approved targeted therapies.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts